Palatin Technologies (PTN) Revenue (2010 - 2026)

Palatin Technologies' (PTN) quarterly Revenue came in at $3.9 million in Q1 2026, up 3278.84% on a QoQ basis from $116036.0 in Q4 2025.

Palatin Technologies (PTN) Revenue (2010 - 2026) Analysis & Trends

Palatin Technologies (PTN) has 14 years of Revenue data on file, last reported at $3.9 million in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.9 million (up 3576.2% YoY) and the FY2024 annual result came in at $4.5 million, down 7.43% from the prior year.
Revenue improved to $3.9 million in Q1 2026, from $116036.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $8.8 million in Q3 2025 to a low of $116036.0 in Q4 2025.
A 5-year average of $1.9 million and a median of $1.1 million in 2022 frame the typical range for Revenue.
Annual changes were most pronounced in 2023 — Revenue soared 453.3% — and 2024, when it tumbled 80.1%.
Tracing PTN's Revenue over 5 years: stood at $1.0 million in 2022, then surged by 98.18% to $2.0 million in 2023, then tumbled by 82.79% to $350000.0 in 2024, then plunged by 66.85% to $116036.0 in 2025, then surged by 3278.84% to $3.9 million in 2026.
The last three Revenue figures came in at $3.9 million (Q1 2026), $116036.0 (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.03 Bn	131.18 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.64 Bn	77.64 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.93 Bn	59.75 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.93 Bn	52.80 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.95 Bn	36.86 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.00 Bn	9.60 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	674.14 Mn
10	Palatin Technologies	40.37 Mn	40.37 Mn	-	3.92 Mn

Download Data